This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heartfailure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
announced that the peer-reviewed Journal of the American College of Cardiology: HeartFailure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heartfailure using commonly accepted willingness-to-pay thresholds. “Our healthcare system.
Differences in heartfailure with preservedejectionfraction (HFpEF) management across medical specialties. Methods and results An independent web-based survey was distributed globally between May and July 2023. A large majority of HFpEF patients are cared by non-cardiologists.
Circulation: HeartFailure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preservedejectionfraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.
Abstract Introduction Heartfailure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejectionfraction (HFrEF), HF with mildly reduced ejectionfraction (HFmrEF), and HF with preservedejectionfraction (HFpEF).
Circulation: HeartFailure, Volume 16, Issue 11 , Page e010849, November 1, 2023. Mediation of the association between MMP-2 and HF was assessed by censoring participants who developed AF or coronary heart disease before HF. 1.81]), incident HF with preservedejectionfraction (1.44 [95% CI, 1.07–1.94]),
Splanchnic ablation for volume management (SAVM) in heartfailure with preservedejectionfraction (HFpEF) was discussed as a late-breaking trial at the HeartFailure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.
Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heartfailure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0
Publication date: Available online 13 April 2024 Source: The American Journal of Cardiology Author(s): Syed Imran Ahmed, Jonathan Kenyon, Hayley E. Billingsley, Hannah Salmons, Natalie J. Bohmke, Roshanak Markley, Antonio Abbate, Danielle L. Kirkman, Youngdeok Kim, Salvatore Carbone
Circulation: HeartFailure, Volume 16, Issue 12 , Page e010673, December 1, 2023. BACKGROUND:Twitch-independent tension has been demonstrated in cardiomyocytes, but its role in heartfailure (HF) is unclear. mm Hg in HF with preservedejectionfraction patients and was also exacerbated by exercise.
Circulation: HeartFailure, Volume 16, Issue 11 , Page e010618, November 1, 2023. BACKGROUND:Obesity and adiposity are associated with an increased risk of heartfailure with preservedejectionfraction (HFpEF); yet, specific underlying mechanisms remain unclear.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heartfailure (HF) with a left ventricular ejectionfraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023. BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heartfailure with mildly reduced or preservedejectionfraction. Controlled BP was defined as BP under threshold.
Circulation: HeartFailure, Volume 16, Issue 11 , Page e010802, November 1, 2023. Heartfailure with preservedejectionfraction (HFpEF) has become the leading form of heartfailure worldwide, particularly among elderly patient populations.
Santos Most Cited Article – Reduction in Hospitalization and Increase in Mortality Due to Cardiovascular Diseases during the COVID-19 Pandemic in Brazil Authors: Paulo Garcia Normando, José de Arimatéia Araujo-Filho, Gabriela de Alcântara Fonseca, Rodrigo Elton Ferreira Rodrigues, Victor Agripino Oliveira, Ludhmila Abrahão Hajjar, André Luiz (..)
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heartfailure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?
LVH is a common etiology of heartfailure with preservedejectionfraction, as it may results in a stiff ventricle with poor diastolic relaxation. LVH can have very thick-walled ventricles and a correspondingly small LV cavity. Can you diagnose HCM ( H ypertrophic C ardio M yopathy ) from today's ECG?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content